U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C9H19N
Molecular Weight 141.2539
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ISOMETHEPTENE

SMILES

CNC(C)CCC=C(C)C

InChI

InChIKey=XVQUOJBERHHONY-UHFFFAOYSA-N
InChI=1S/C9H19N/c1-8(2)6-5-7-9(3)10-4/h6,9-10H,5,7H2,1-4H3

HIDE SMILES / InChI

Molecular Formula C9H19N
Molecular Weight 141.2539
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including https://clinicaltrials.gov/ct2/show/NCT02290379 | https://www.ncbi.nlm.nih.gov/pubmed/22288671 | https://clinicaltrials.gov/ct2/show/NCT02706015 | https://www.drugbank.ca/drugs/DB06706

Isometheptene (usually as isometheptene mucate) is a sympathomimetic amine sometimes used in the treatment of migraines and tension headaches due to its vasoconstricting properties. Isometheptene's vasoconstricting properties arise through activation of the sympathetic nervous system via epinephrine and norepinephrine. These compounds elicit smooth muscle activation leading to vasoconstriction by interacting with cell surface adrenergic receptors.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Neosaldina

Approved Use

Unknown
Primary
Neosaldina

Approved Use

Unknown
Primary
Neosaldina

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
120 mg 1 times / episode multiple, oral
Studied dose
Dose: 120 mg, 1 times / episode
Route: oral
Route: multiple
Dose: 120 mg, 1 times / episode
Sources:
unhealthy, 18 to 65 years
Health Status: unhealthy
Age Group: 18 to 65 years
Sex: M+F
Sources:
Other AEs: Angioneurotic edema, Epigastralgia...
Other AEs:
Angioneurotic edema (grade 1, 1.3%)
Epigastralgia (grade 1, 1.3%)
Sources:
780 mg 1 times / episode multiple, oral
Studied dose
Dose: 780 mg, 1 times / episode
Route: oral
Route: multiple
Dose: 780 mg, 1 times / episode
Sources:
unhealthy, mean age 33 years
Health Status: unhealthy
Age Group: mean age 33 years
Sex: M+F
Sources:
Other AEs: Dizziness, Numbness...
Other AEs:
Dizziness (17.1%)
Numbness (5.7%)
Shortness of breath (2.8%)
Chills (2.8%)
Nausea (2.8%)
Drowsiness (2.8%)
Sources:
65 mg 1 times / hour multiple, oral
Recommended
Dose: 65 mg, 1 times / hour
Route: oral
Route: multiple
Dose: 65 mg, 1 times / hour
Sources:
unhealthy, mean age 40.9 years
Health Status: unhealthy
Age Group: mean age 40.9 years
Sex: M+F
Sources:
Other AEs: Abdominal pain, Nausea...
Other AEs:
Abdominal pain (3.1%)
Nausea (3.1%)
Lightheadedness (6.1%)
Sleepiness (3.1%)
Dry mouth (1.5%)
Hot flashes (1.5%)
Palpitations (1.5%)
Enlarged thyroid (1.5%)
Confusion (1.5%)
Sources:
325 mg 1 times / episode multiple, oral
Recommended
Dose: 325 mg, 1 times / episode
Route: oral
Route: multiple
Dose: 325 mg, 1 times / episode
Sources:
unhealthy, mean age 49 years
Health Status: unhealthy
Age Group: mean age 49 years
Sex: M+F
Sources:
Other AEs: Nausea, Vertigo...
Other AEs:
Nausea (40%)
Vertigo (8%)
Lump feeling in throat (8%)
Drowsiness (4%)
Tachycardia (4%)
Itching (4%)
Dry mouth (4%)
Weakness of limbs (4%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Angioneurotic edema grade 1, 1.3%
120 mg 1 times / episode multiple, oral
Studied dose
Dose: 120 mg, 1 times / episode
Route: oral
Route: multiple
Dose: 120 mg, 1 times / episode
Sources:
unhealthy, 18 to 65 years
Health Status: unhealthy
Age Group: 18 to 65 years
Sex: M+F
Sources:
Epigastralgia grade 1, 1.3%
120 mg 1 times / episode multiple, oral
Studied dose
Dose: 120 mg, 1 times / episode
Route: oral
Route: multiple
Dose: 120 mg, 1 times / episode
Sources:
unhealthy, 18 to 65 years
Health Status: unhealthy
Age Group: 18 to 65 years
Sex: M+F
Sources:
Dizziness 17.1%
780 mg 1 times / episode multiple, oral
Studied dose
Dose: 780 mg, 1 times / episode
Route: oral
Route: multiple
Dose: 780 mg, 1 times / episode
Sources:
unhealthy, mean age 33 years
Health Status: unhealthy
Age Group: mean age 33 years
Sex: M+F
Sources:
Chills 2.8%
780 mg 1 times / episode multiple, oral
Studied dose
Dose: 780 mg, 1 times / episode
Route: oral
Route: multiple
Dose: 780 mg, 1 times / episode
Sources:
unhealthy, mean age 33 years
Health Status: unhealthy
Age Group: mean age 33 years
Sex: M+F
Sources:
Drowsiness 2.8%
780 mg 1 times / episode multiple, oral
Studied dose
Dose: 780 mg, 1 times / episode
Route: oral
Route: multiple
Dose: 780 mg, 1 times / episode
Sources:
unhealthy, mean age 33 years
Health Status: unhealthy
Age Group: mean age 33 years
Sex: M+F
Sources:
Nausea 2.8%
780 mg 1 times / episode multiple, oral
Studied dose
Dose: 780 mg, 1 times / episode
Route: oral
Route: multiple
Dose: 780 mg, 1 times / episode
Sources:
unhealthy, mean age 33 years
Health Status: unhealthy
Age Group: mean age 33 years
Sex: M+F
Sources:
Shortness of breath 2.8%
780 mg 1 times / episode multiple, oral
Studied dose
Dose: 780 mg, 1 times / episode
Route: oral
Route: multiple
Dose: 780 mg, 1 times / episode
Sources:
unhealthy, mean age 33 years
Health Status: unhealthy
Age Group: mean age 33 years
Sex: M+F
Sources:
Numbness 5.7%
780 mg 1 times / episode multiple, oral
Studied dose
Dose: 780 mg, 1 times / episode
Route: oral
Route: multiple
Dose: 780 mg, 1 times / episode
Sources:
unhealthy, mean age 33 years
Health Status: unhealthy
Age Group: mean age 33 years
Sex: M+F
Sources:
Confusion 1.5%
65 mg 1 times / hour multiple, oral
Recommended
Dose: 65 mg, 1 times / hour
Route: oral
Route: multiple
Dose: 65 mg, 1 times / hour
Sources:
unhealthy, mean age 40.9 years
Health Status: unhealthy
Age Group: mean age 40.9 years
Sex: M+F
Sources:
Dry mouth 1.5%
65 mg 1 times / hour multiple, oral
Recommended
Dose: 65 mg, 1 times / hour
Route: oral
Route: multiple
Dose: 65 mg, 1 times / hour
Sources:
unhealthy, mean age 40.9 years
Health Status: unhealthy
Age Group: mean age 40.9 years
Sex: M+F
Sources:
Enlarged thyroid 1.5%
65 mg 1 times / hour multiple, oral
Recommended
Dose: 65 mg, 1 times / hour
Route: oral
Route: multiple
Dose: 65 mg, 1 times / hour
Sources:
unhealthy, mean age 40.9 years
Health Status: unhealthy
Age Group: mean age 40.9 years
Sex: M+F
Sources:
Hot flashes 1.5%
65 mg 1 times / hour multiple, oral
Recommended
Dose: 65 mg, 1 times / hour
Route: oral
Route: multiple
Dose: 65 mg, 1 times / hour
Sources:
unhealthy, mean age 40.9 years
Health Status: unhealthy
Age Group: mean age 40.9 years
Sex: M+F
Sources:
Palpitations 1.5%
65 mg 1 times / hour multiple, oral
Recommended
Dose: 65 mg, 1 times / hour
Route: oral
Route: multiple
Dose: 65 mg, 1 times / hour
Sources:
unhealthy, mean age 40.9 years
Health Status: unhealthy
Age Group: mean age 40.9 years
Sex: M+F
Sources:
Abdominal pain 3.1%
65 mg 1 times / hour multiple, oral
Recommended
Dose: 65 mg, 1 times / hour
Route: oral
Route: multiple
Dose: 65 mg, 1 times / hour
Sources:
unhealthy, mean age 40.9 years
Health Status: unhealthy
Age Group: mean age 40.9 years
Sex: M+F
Sources:
Nausea 3.1%
65 mg 1 times / hour multiple, oral
Recommended
Dose: 65 mg, 1 times / hour
Route: oral
Route: multiple
Dose: 65 mg, 1 times / hour
Sources:
unhealthy, mean age 40.9 years
Health Status: unhealthy
Age Group: mean age 40.9 years
Sex: M+F
Sources:
Sleepiness 3.1%
65 mg 1 times / hour multiple, oral
Recommended
Dose: 65 mg, 1 times / hour
Route: oral
Route: multiple
Dose: 65 mg, 1 times / hour
Sources:
unhealthy, mean age 40.9 years
Health Status: unhealthy
Age Group: mean age 40.9 years
Sex: M+F
Sources:
Lightheadedness 6.1%
65 mg 1 times / hour multiple, oral
Recommended
Dose: 65 mg, 1 times / hour
Route: oral
Route: multiple
Dose: 65 mg, 1 times / hour
Sources:
unhealthy, mean age 40.9 years
Health Status: unhealthy
Age Group: mean age 40.9 years
Sex: M+F
Sources:
Drowsiness 4%
325 mg 1 times / episode multiple, oral
Recommended
Dose: 325 mg, 1 times / episode
Route: oral
Route: multiple
Dose: 325 mg, 1 times / episode
Sources:
unhealthy, mean age 49 years
Health Status: unhealthy
Age Group: mean age 49 years
Sex: M+F
Sources:
Dry mouth 4%
325 mg 1 times / episode multiple, oral
Recommended
Dose: 325 mg, 1 times / episode
Route: oral
Route: multiple
Dose: 325 mg, 1 times / episode
Sources:
unhealthy, mean age 49 years
Health Status: unhealthy
Age Group: mean age 49 years
Sex: M+F
Sources:
Itching 4%
325 mg 1 times / episode multiple, oral
Recommended
Dose: 325 mg, 1 times / episode
Route: oral
Route: multiple
Dose: 325 mg, 1 times / episode
Sources:
unhealthy, mean age 49 years
Health Status: unhealthy
Age Group: mean age 49 years
Sex: M+F
Sources:
Tachycardia 4%
325 mg 1 times / episode multiple, oral
Recommended
Dose: 325 mg, 1 times / episode
Route: oral
Route: multiple
Dose: 325 mg, 1 times / episode
Sources:
unhealthy, mean age 49 years
Health Status: unhealthy
Age Group: mean age 49 years
Sex: M+F
Sources:
Weakness of limbs 4%
325 mg 1 times / episode multiple, oral
Recommended
Dose: 325 mg, 1 times / episode
Route: oral
Route: multiple
Dose: 325 mg, 1 times / episode
Sources:
unhealthy, mean age 49 years
Health Status: unhealthy
Age Group: mean age 49 years
Sex: M+F
Sources:
Nausea 40%
325 mg 1 times / episode multiple, oral
Recommended
Dose: 325 mg, 1 times / episode
Route: oral
Route: multiple
Dose: 325 mg, 1 times / episode
Sources:
unhealthy, mean age 49 years
Health Status: unhealthy
Age Group: mean age 49 years
Sex: M+F
Sources:
Lump feeling in throat 8%
325 mg 1 times / episode multiple, oral
Recommended
Dose: 325 mg, 1 times / episode
Route: oral
Route: multiple
Dose: 325 mg, 1 times / episode
Sources:
unhealthy, mean age 49 years
Health Status: unhealthy
Age Group: mean age 49 years
Sex: M+F
Sources:
Vertigo 8%
325 mg 1 times / episode multiple, oral
Recommended
Dose: 325 mg, 1 times / episode
Route: oral
Route: multiple
Dose: 325 mg, 1 times / episode
Sources:
unhealthy, mean age 49 years
Health Status: unhealthy
Age Group: mean age 49 years
Sex: M+F
Sources:
PubMed

PubMed

TitleDatePubMed
Epidemiological analysis of doping offences in the professional tennis circuit.
2010-12-15
Managing traumatic brain injury secondary to explosions.
2010-04
Rizatriptan for the acute treatment of migraine: Consistency, preference, satisfaction, and quality of life.
2009-11-03
Life threatening intracerebral hemorrhage with isometheptene mucate, dichlorophenazine and acetaminophen combination therapy.
2009-11
Current and prospective pharmacological targets in relation to antimigraine action.
2008-10
Acute migraine: Current treatment and emerging therapies.
2007-06
Effects of current and prospective antimigraine drugs on the porcine isolated meningeal artery.
2006-12
Intracerebral hemorrhage in postpartum cerebral angiopathy associated with the use of isometheptene.
2006-11
Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study.
2006-06
Metabolism of isometheptene in human urine and analysis by gas chromatography-mass spectrometry in doping control.
2005-12-05
Fixed drug combinations for the acute treatment of migraine : place in therapy.
2005
Pharmacological analysis of the mechanisms involved in the tachycardic and vasopressor responses to the antimigraine agent, isometheptene, in pithed rats.
2004-05-14
Medication use by persons with chronic fatigue syndrome: results of a randomized telephone survey in Wichita, Kansas.
2003-12-02
Migraine: diagnosis, management, and new treatment options.
2002-02
Pharmacological profile of the mechanisms involved in the external carotid vascular effects of the antimigraine agent isometheptene in anaesthetised dogs.
2001-07
Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine.
2001-04
Patents

Patents

Sample Use Guides

Single dose 1 to 2 tablets/days, Daily Maximum Dose: 8 tablets (4 x 2 dragees). One tablet contains 30 mg of Isometheptene Mucate.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:55:51 GMT 2025
Edited
by admin
on Mon Mar 31 17:55:51 GMT 2025
Record UNII
Y7L24THH6T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ISOMETHEPTENE
INN   MART.   MI   WHO-DD  
INN  
Official Name English
ISONYL
Preferred Name English
ISOMETHEPTENE [MART.]
Common Name English
isometheptene [INN]
Common Name English
N,1,5-TRIMETHYL-4-HEXENYLAMINE
Systematic Name English
ISOMETHEPTENE [MI]
Common Name English
6-METHYLAMINO-2-METHYLHEPTENE
Systematic Name English
OCTIN
Brand Name English
4-HEXENYLAMINE, N,1,5-TRIMETHYL-
Systematic Name English
2-METHYL-6-METHYLAMINO-2-HEPTENE
Systematic Name English
N,6-DIMETHYL-5-HEPTEN-2-AMINE
Systematic Name English
OCTANIL
Brand Name English
5-HEPTEN-2-AMINE, N,6-DIMETHYL-
Systematic Name English
Isometheptene [WHO-DD]
Common Name English
Classification Tree Code System Code
LIVERTOX 520
Created by admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
WHO-ATC A03AX10
Created by admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
NCI_THESAURUS C29747
Created by admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
WHO-VATC QA03AX10
Created by admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
Code System Code Type Description
INN
576
Created by admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
PRIMARY
RXCUI
27946
Created by admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
PRIMARY RxNorm
PUBCHEM
22297
Created by admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
PRIMARY
NCI_THESAURUS
C75929
Created by admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
PRIMARY
ECHA (EC/EINECS)
207-959-6
Created by admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
PRIMARY
CAS
65783-53-1
Created by admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
SUPERSEDED
DRUG BANK
DB06706
Created by admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
PRIMARY
MERCK INDEX
m6501
Created by admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
PRIMARY Merck Index
EVMPD
SUB08324MIG
Created by admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
PRIMARY
ChEMBL
CHEMBL1697841
Created by admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
PRIMARY
SMS_ID
100000082812
Created by admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
PRIMARY
MESH
C008192
Created by admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
PRIMARY
EPA CompTox
DTXSID9023172
Created by admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
PRIMARY
CAS
503-01-5
Created by admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
PRIMARY
FDA UNII
Y7L24THH6T
Created by admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
PRIMARY
DRUG CENTRAL
1496
Created by admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
PRIMARY
WIKIPEDIA
Isometheptene
Created by admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
ENANTIOMER -> RACEMATE
Related Record Type Details
ACTIVE MOIETY